[Effect of 3,4-dihydroxyacetophenone treatment on intrauterine growth retardation].
In this paper, the results of a pilot study of 3,4-dihydroxyacetophenone (DHAP) treatment for intrauterine growth retardation (IUGR) were reported. 20 out of 38 cases of IUGR were treated with DHAP and 18 with amino acid. Additionally, 170 normal pregnant women were served as control group. The following parameters have been observed and measured including uterine fundal height (UFH), body weight (BW), S/D ratio of umbilical artery (UmA), hemorheological indices, platelets aggregation, TXB2/6-keto-PGF1 alpha ratio and also fetal and neonatal various growth indices etc. After administration of DHAP, all the parameters almost restored to the normal range. The results expressed that the therapeutic effect of DHAP was much better than that of amino acid. It has also been verified by neonatal birth weight and fetal biparietal diameter. The clinical effective rate of DHAP treatment group was 90.00% which was significantly higher than that 74.00%, 79.00% of amino-acid treatment group. Meanwhile, the mechanism of DHAP has preliminarily been discussed.
Huang
Y P
YP
Tongji Hospital, Tongji Medical University, Wuhan.
Ma
T Y
TY
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000098:Acetophenones / Q000627:therapeutic use*; D005260:Female; D005317:Fetal Growth Retardation / Q000188:drug therapy*; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011247:Pregnancy; D013929:Thromboxane B2 / Q000097:blood
D000098:Acetophenones; D010975:Platelet Aggregation Inhibitors; C032940:3,4-dihydroxyacetophenone; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha